Drug profile · INN
cosibelimab-ipdl
UNLOXCYT
cosibelimab-ipdl (UNLOXCYT) is a programmed cell death 1 ligand 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — cosibelimab-ipdl
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
cosibelimab-ipdl (UNLOXCYT) is a programmed cell death 1 ligand 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death 1 ligand 1 inhibitor
Primary target: Programmed cell death 1 ligand 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cosibelimab-ipdl?
cosibelimab-ipdl (UNLOXCYT) is a programmed cell death 1 ligand 1 inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for cosibelimab-ipdl?
UNLOXCYT is a marketed brand name for cosibelimab-ipdl. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cosibelimab-ipdl?
cosibelimab-ipdl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.